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 Clinical trials that are randomised in clusters often include an assessment of participants’ 
outcomes in a baseline period. 
 
 The analysis of cluster randomised trials is more complex than for individually randomised trials. 
A variety of methods have been suggested to allow for baseline assessments of outcome. 
 
 We recommend either an analysis of covariance approach which takes account of cluster 
differences at baseline, or an analysis which treats assessments at baseline and follow-up as 
longitudinal but which recognises that there will not be any systematic differences between the 
randomised groups at baseline. 
 
 Simply comparing the difference between outcomes at baseline and follow-up in the two 
randomised groups – that is, calculating the difference of differences – is not the best approach, 
and can be misleading. 
 
  
In a cluster randomised clinical trial all the participants who belong to the same “cluster” (e.g. a local 
community, school or general practice) are randomised to receive the same treatment. People from 
the same cluster tend to be more similar than those from different clusters, and the analysis must 
allow for this.1 A common enhancement is to add an assessment of participants’ outcomes in a 
baseline period, i.e. before randomisation. Even if different participants are assessed at baseline and 
follow-up the fact that they are sampled from the same cluster allows some control for cluster 
differences. But the analysis of cluster randomised trials is more complex than for individually 
randomised trials, and it is not obvious how best to adjust for baseline assessments. A variety of 
methods of analysis have been suggested: here we describe different approaches and their flaws, 




The decision to randomise a trial in clusters is usually a pragmatic one: the intervention might be 
delivered at cluster level, for example, or there might otherwise be a risk of people in the same 
cluster sharing their treatments, and thus attenuating treatment effects. Three illustrative cluster 
randomised trials which include a baseline assessment of participants’ outcomes are described in 
Boxes 1-3. Coventry and colleagues (Box 1), for example, used a cluster randomised design with 
general practices as clusters to look at the effectiveness of an integrated collaborative care model 
for people with depression and long term physical conditions.2 
 
The sample size required for a cluster randomised trial is larger than for an individually randomised 
trial: how much larger depends on a parameter called the intracluster correlation – the correlation 
between the outcomes of two individuals from the same cluster.3 The higher the intracluster 
correlation, the more heterogeneity there is between clusters, and the greater the advantage in 
controlling for cluster differences, for example with a baseline assessment.4 Researchers might 
choose to assess the same individuals at baseline and follow-up (a cohort design) or to take different 
samples from the same cluster on the two occasions (repeated cross-sections), and this may again 
be a pragmatic decision. Costantini and colleagues (Box 2) studied the quality of end-of-life care in 
patients with cancer, leading them to a design in which they recruited different samples from each 
hospital ward at baseline and follow-up.5 
 
Approaches to analysis 
 
Difference of differences 
 
One method for estimating the effect of an intervention in a trial with clusters randomised to 
intervention and control groups, and assessments at baseline and follow-up, is with a longitudinal 
repeated measures analysis that tests for a statistical interaction between group and time. This is 
sometimes called a difference of differences analysis because it evaluates how much the groups 
differ in terms of the difference between outcomes at baseline and follow-up. This was the approach 
used by He and colleagues to evaluate a school-based education programme aimed at reducing salt 
intake in children and their families (Box 3), for example.6 
 
In individually randomised trials the shortcomings of a difference of differences approach (more 
usually known in this case as a change score analysis) are well understood.7,8 If the baseline 
assessment is only poorly correlated with the follow-up then subtracting the baseline outcome just 
adds random noise to the signal we are trying to detect. Worse still, if the two groups differ 
markedly (by chance) at baseline and then level themselves out at follow-up we might be misled by 
the difference of differences into thinking that a change had been effected in one group but not the 
other (regression to the mean).9 The problem is that the analysis does not use what we know: before 
randomisation outcomes in the two groups should, on average, be the same. 
 
Analysis of covariance 
 
The method usually recommended for baseline adjustment in an individually randomised trial is 
analysis of covariance, or ANCOVA.7 Adjustment in cluster randomised trials is more complex. We 
consider repeated cross-section and cohort designs in turn. 
 
In a repeated cross-section design, where there are different individuals at baseline and follow-up, a 
simple way to deal with baseline assessments of outcomes is to bundle them up in each cluster as a 
mean or other aggregate measure, to form a cluster-level covariate. Outcomes at follow-up can then 
be analysed either at aggregate cluster level or as individual outcomes, in either case adjusting for 
the cluster-level baseline covariate. If analysing individual outcomes at follow-up then the analysis 
must also allow for clustering using mixed regression or generalised estimating equations (GEE), as 
with any cluster randomised trial.1 This was the method used by Costantini and colleagues (Box 2):5 
each patient’s quality of care score at follow-up was adjusted for the mean quality of care score 
found in that hospital ward at baseline. 
 
In a cohort design, where the same individuals are assessed at baseline and follow-up, an obvious 
approach to ANCOVA is to analyse each individual’s outcome at follow-up adjusted for that 
individual’s outcome at baseline, with mixed regression or GEE to allow for differences between 
clusters. This ANCOVA approach with individual-level baseline adjustment was the method used by 
Coventry and colleagues (Box 1):2 each participant’s depression scale score at follow-up was 
adjusted for his or her score at baseline, thus allowing for participant differences. In a 
methodological paper that deserves more attention, however, Klar and Darlington found that even 
more precise results could be obtained by adjusting an individual’s outcome at follow-up both for 
the individual’s baseline assessment and for the baseline cluster mean.10 In the Coventry example 
this would be achieved by adjusting also for the mean of the baseline depression scores of all 
patients from the same practice. The baseline cluster mean captures more information about cluster 
differences than the individual baseline assessment. 
 
Constrained baseline analysis 
 
In individually randomised trials an alternative to ANCOVA is to treat outcomes collected at baseline 
and follow-up as longitudinal, and to use a repeated measures analysis to estimate the effect of the 
intervention being “switched on” in one of the randomised groups on the second of these 
occasions.11 This is sometimes referred to as a constrained baseline analysis because, unlike a 
difference of differences analysis, it assumes there is no systematic difference between the groups 
at baseline. In cluster randomised trials this is a special case of the approach to analysis 
recommended more generally for stepped wedge trials (cluster randomised trials where outcomes 
are assessed at multiple time-points, and different clusters switch over to the intervention at 
different times).12 Two ways of doing this have been described in the literature: one assumes that 
the correlation between two people from the same cluster is the same whether they are sampled in 
the same period or a different period,13 while the other allows the correlation to be weaker between 
different periods.14–16 The distinction is technical but important. A study using The Health 
Improvement Network (THIN) general practice database found that, for the health outcomes 
investigated (HbA1c, systolic and diastolic blood pressure, body mass index, total cholesterol, and 
HDL cholesterol), correlations between individuals from the same practice were between 12% and 
51% smaller when those individuals were sampled from different 15-month periods,17 motivating 
the use of the second, more flexible model. A constrained baseline analysis that lacks this flexibility 
in the correlation structure is known to over-state the precision of the treatment effect, potentially 
leading to false-positive findings.15 
 
In the cluster randomised case a constrained baseline analysis might be expected to produce similar 
results to ANCOVA, as in the individually randomised case.11 The method is extremely flexible, is 
available in cohort or repeated cross-section forms, and allows an analysis based on individual-level 
data, with no aggregation needed either at baseline or at follow-up. 
 
Some benefits of aggregating outcomes by cluster 
 
When a cluster randomised trial involving relatively few clusters – fewer than 40, say – is analysed 
with mixed regression or GEE there is known to be an increased risk of a false positive finding (an 
inflated Type I error rate) unless an appropriate correction is made.18 Corrections such as that of 
Kenward and Roger are increasingly accessible, and should be considered in such cases.19 For 
repeated cross-section designs, one benefit of performing an ANCOVA entirely at the cluster level – 
aggregating follow-up outcomes by cluster and adjusting for the aggregate baseline outcome – is 
that a mixed regression or GEE approach is unnecessary. This greatly simplifies the analysis and 
keeps the risk of false positive findings under control. But could this also help with cohort designs?  
Theory shows that if the correlation between the baseline cluster mean and the mean at follow-up 
in the same cluster is known, it is immaterial whether it was the same participants who were 
assessed on each occasion or different participants: the precision of the treatment effect estimate 
will be the same.14 This suggests that if we treated a cohort design as if it were a repeated cross-
section design, and adjusted purely at the aggregate, cluster level rather than the individual level, 
the analysis would perform just as well. Indeed, in some situations cluster-level and individual-level 
analyses of cohort designs do give identical results (see online supplement). 
 
Individual-level baseline adjustment also runs into difficulties if some participants in a cohort design 
have missing baseline assessments. ANCOVA with individual-level baseline adjustment requires us in 
this case either to impute the missing baseline assessments or to exclude those individuals from the 
analysis. Adjusting only for a baseline cluster mean offers a straightforward analysis of all available 
data without the need to impute or exclude data, but there are still difficulties in this case: 
participants who are assessed at baseline but have a missing follow-up assessment still warrant 
individual attention, as the baseline could offer a valuable clue to the unobserved outcome (and 
reasons for dropping out).20 As observed above, a constrained baseline analysis offers an alternative 
using all available data, but at the individual level. Note finally that in some trials having a missing 




The online supplement provides tutorials showing how to implement the analyses described above 
using the Stata package (Stata Corporation, College Station TX, USA). The supplement also includes 
results of large-scale simulations of trials in typical scenarios which illustrate some of the 
performance issues outlined. A constrained baseline analysis with a realistic correlation structure 
performed consistently well for both cohort and repeated cross-section designs, as did (more 
surprisingly) an ANCOVA performed entirely at the cluster level. A constrained baseline analysis with 
less flexible correlation structure risked an inflated Type I error rate in some scenarios, while a 
difference of differences analysis and ANCOVA with purely individual-level baseline adjustment did 
not always achieve the statistical power that was expected. 
 
Further work, including simulation studies, is needed to quantify the performance of different 
methods in a broader range of circumstances than we have been able to consider here. We only 
looked at balanced situations where equal numbers of participants are sampled from each cluster at 
each assessment. (Klar and Darlington also provided simulations of unbalanced situations.)10 
Methods outlined in this article can be applied to unbalanced designs, though lack of balance 
introduces further subtleties: aggregating outcomes at cluster level, for example, may not be the 
most efficient way to weight the contribution of clusters of different size. We have emphasised the 
importance of getting the right model for the correlation structure, but there may be complexities 
beyond those we have considered: outcomes at baseline and follow-up may correlate in different 




The analysis of a cluster randomised trial with a baseline assessment of outcome is not as 
straightforward as it might seem, but the advice is similar for cohort and for cross-sectional designs. 
ANCOVA should adjust for the baseline cluster mean, even in a cohort design where individual-level 
baseline adjustment is also possible. A good, all-round alternative to ANCOVA is a constrained 
baseline analysis with a suitably flexible model for the correlation between individuals from the 
same cluster. We do not recommend a difference of differences analysis for a cluster randomised 
trial. Any analysis using mixed regression or generalised estimating equations has an increased risk 
of a false positive finding when there are relatively few clusters, so analysts should apply a 
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Box 1. Integrated primary care for patients with mental and physical multimorbidity: cluster 
randomised controlled trial of collaborative care for patients with depression comorbid with 
diabetes or cardiovascular disease. Coventry et al, BMJ 2015;350:h638 
 
Objective: To test the effectiveness of an integrated collaborative care model for people with 
depression and long term physical conditions. 
 
Primary Outcome: Symptoms of depression on the self-reported symptom checklist-13 depression 
scale (SCL-D13). 
 
Planned sample Size: 15 general practices (clusters) per arm and 15 patients per cluster (n=450) to 
detect a difference between groups equivalent to a standardised effect size of 0.4, with 80% power 
(α=0.05; intraclass correlation coefficient 0.06), allowing for 20% attrition. 
 
Design & Analysis: Patients registered at a participating practice who had a record of diabetes 
and/or coronary heart disease were screened for depressive symptoms over the telephone, and 
face-to-face two weeks later, to determine eligibility. Participants’ depression scale scores were 
collected at baseline and again after 4 months follow-up (a cohort design). Outcomes at follow-up 
were compared between the intervention and control arms. Analysis was conducted at the 




Box 2. Liverpool Care Pathway for patients with cancer in hospital: a cluster randomised trial. 
Costantini et al, Lancet 2014;383:226–237 
 
Objective: To assess the effectiveness of the Liverpool Care Pathway translated into an Italian 
context (LCP-I) in improving the quality of end-of-life care for patients with cancer in hospitals and 
for their families. 
 
Primary Outcome: Mean score on the overall quality of care toolkit scale. 
 
Planned sample Size: 10 hospital wards (clusters) per arm and 20 patients per cluster (n=400) to 
detect an absolute increase of 10 points on the toolkit scale, with 80% power (α=0.05; intraclass 
correlation coefficient 0.1). 
 
Design & Analysis: In each ward, all patients who died in the 3 months before randomisation and in 
the 6 months after the conclusion of the LCP-I programme were identified (a repeated cross-section 
design) and their quality of end-of-life care was assessed. Outcomes at follow-up were compared 
between the intervention and control arms. Analysis was at the individual level, adjusting for 





Box 3. School based education programme to reduce salt intake in children and their families 
(School-EduSalt): cluster randomised controlled trial. He et al, BMJ 2015;350:h770 
 
Objective: To determine whether an education programme targeted at schoolchildren could lower 
salt intake in children and their families. 
 
Primary Outcome: Salt intake (measured as urinary sodium excretion, averaged over two  
consecutive 24-hour collections). 
 
Planned sample size: 12 schools (clusters) per arm and 10 children per cluster (n=240) to detect a 
difference in salt intake of 1.0g a day, with 90% power (α=0.05; intraclass correlation coefficient 
0.01). 
 
Design & Analysis: One class was selected from each school, and 10 children were randomly selected 
from each class. Each child’s urinary sodium was measured at baseline and again after 6 months 
follow-up (a cohort design). Analysis was at the individual level, and compared the change from 
baseline to follow-up between the intervention and control arms. 
 
 
 
